Adverse Events and Tolerability of Combined Durvalumab and Tremelimumab versus Durvalumab Alone in Solid Cancers: A Systematic Review and Meta-Analysis.

Biomedicines · 2022 · PMC9138649 · PMID 35625837

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

just below the significance levelno p-value reported

monotherapy was also higher, even though with marginal p -value, just below the significance level.

also in 29 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.